Table 1 Study design and participant characteristics
Authors, year | Study design | Type and stage of cancer | Group | Sample (n) | Age (year) | Gender (M:F) | BMI (kg/m2) | Neoadjuvant treatment (n%) |
|---|---|---|---|---|---|---|---|---|
Christensen et al., 2019 [26] | Non-randomized controlled trial | Gastroesophageal junction, I–III | IG UC | 21 29 | 63.9 ± 8.2 65.5 ± 7.3 | 18:3 27:2 | 28.4 ± 5.6 27.8 ± 5.5 | CT: 90%, CRT: 10% CT: 85%, CRT: 15% |
Dettling et al., 2013 [17] | Pilot, non-randomized controlled study | Esophageal, NR | IG UC | 44 39 | 65.1 ± 7.5 66.5 ± 9.6 | 33:11 29:10 | 24.9 ± 2.9 25.9 ± 2.9 | CRT: 71% CRT: 44% |
Inoue et al., 2013 [22] | Retrospective study | Esophageal, 0-IV | IG UC | 63 37 | 67.4 ± 9.0 65.0 ± 7.8 | 53:10 34:3 | 20.7 ± 2.9 21.1 ± 2.7 | CT: 68% CT: 43% |
Valkenet et al., 2018 [23] | RCT | Esophageal, 0-IV | IG UC | 120 121 | 63.7 ± 7.5 62.7 ± 8.9 | 89:31 97:24 | 26.7 ± 4.8 26.5 ± 5.2 | CT: 8%, CRT: 78% CT: 10%, CRT: 78% |
van Adrichem et al., 2014 [24] | Pilot, RCT | Esophageal, NR | IMT-HI IMT-E | 20 19 | 62.7 ± 7.1 61.3 ± 7.3 | 15:5 14:5 | 23.9 (22.8–28.7) 25.7 (22.6–28.1) | CRT: 90% CRT: 95% |
Yamana et al., 2015 [18] | RCT | Esophageal, 0-IV | IG UC | 30 30 | 68.3 ± 7.6 65.9 ± 9.5 | 24:6 23:7 | 21.8 ± 2.7 20.9 ± 2.5 | CT: 43%, RT: 10% CT: 50%, RT: 17% |
Cho et al., 2014 [25] | Prospective matching study | Gastric, I-III | IG UC | 18 54 | 63.1 (51–76) 66.1 (39–81) | 18:0 51:3 | 26.7 (23.1–31.2) 25.6 (20.8–34.1) | None None |